Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology)

重组抗PD-1人源化单克隆抗体（安徽安科生物）

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRecombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology)
Drug Alias Name重组抗PD1人源化单克隆抗体注射液（安徽安科生物）重组人源化抗PD-1单克隆抗体注射液（安徽安科生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsLung NeoplasmsEsophageal NeoplasmsTriple Negative Breast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnhui Anke Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsLung NeoplasmsEsophageal NeoplasmsTriple Negative Breast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A